| Literature DB >> 32256645 |
Jinke Huang1, Min Shen1, Xiaohui Qin2, Weichi Guo1, Hui Li3,4.
Abstract
OBJECTIVES: Because current evidence regarding the effectiveness of acupuncture for a tension-type headache (TTH) is controversial, we evaluated the reliability of the methodological quality and outcome measures of systematic reviews/meta-analyses (SRs/MAs) on acupuncture for TTH.Entities:
Year: 2020 PMID: 32256645 PMCID: PMC7106880 DOI: 10.1155/2020/4262910
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Search strategy for the PubMed database.
| Query | Search term |
|---|---|
| # 1 | Tension-type headache [mesh] |
| # 2 | Tension-type headache∗[title/abstract] OR tension type headache∗[title/abstract] OR idiopathic headache∗[title/abstract] OR stress headache∗[title/abstract] OR tension headache∗[title/abstract] OR psychogenic headache∗[title/abstract] |
| # 3 | #1 OR #2 |
| # 4 | Acupuncture [mesh] |
| # 5 | Acupuncture [title/abstract] OR pharmacoacupuncture [title/abstract] OR acupotomy[title/abstract] OR acupotomies [title/abstract] OR pharmacopuncture[title/abstract] OR needle [title/abstract] OR needling [title/abstract] OR dry-needling[title/abstract] OR body-acupuncture [title/abstract] OR electro-acupuncture [title/abstract] OR electro-acupuncture [title/abstract] OR auricular acupuncture [title/abstract] |
| # 6 | #4 OR #5 |
| # 7 | Meta-analysis as topic [mesh] |
| # 8 | Meta-analysis [publication type] |
| # 9 | Systematic review [title/abstract] OR meta-analysis [title/abstract] OR meta-analysis [title/abstract] OR meta-analyses [title/abstract] OR meta-analysis [title/abstract] |
| # 10 | #7 OR #8 OR #9 |
| # 11 | #3 AND #6 AND #10 |
Figure 1Flow diagram of the literature selection process.
Characteristics of the included reviews.
| First author; year | Country | Trials (sample size) | Treatment intervention | Control intervention | Quality assessment tool | Overall conclusion |
|---|---|---|---|---|---|---|
| Deng [ | China | 12 (933) | AT; AT + CPM; AT + MT | CPM; MT | Cochrane criteria | Acupuncture treatment of TTH has certain advantages. |
| Zhang et al. [ | China | 10 (1071) | AT | SAT; NSAIDs | Jadad score | The acupuncture treatment is effective for TTH, and the therapeutic effect is better than NSAIDs. |
| Lin and Xiao [ | China | 9 (598) | AT | MT | Cochrane criteria | The therapeutic effect of acupuncture on TTH has certain advantages compared with MT. |
| Li and Luo [ | China | 13 (571) | AT | SAT; other physical therapies; MT | Jadad score | Comparing acupuncture with sham acupuncture and other treatments, current evidence cannot evaluate whether acupuncture is significantly effective for TTH. |
| Linde et al. [ | Germany | 11 (2349) | AT | SAT; other physical therapies | Cochrane criteria | AT is effective for treating frequent episodic or chronic TTH. |
| Hao et al. [ | Australian | 5 (838) | AT | SAT | Jadad score | AT stimulation mode, needle retention, and treatment frequency could be important factors contributing to the outcome of acupuncture for TTH. |
| Davis et al. [ | American | 8 (896) | AT | SAT | Jadad score | The results suggest that AT compared with sham for TTH has limited efficacy for the reduction of headache frequency. |
| Sun and Gan [ | American | 25 (3916) | AT | SAT; other physical therapies | Jadad score | AT is superior to SAT and MT in improving headache intensity, frequency, and response rate. |
AT: acupuncture therapy; SAT: sham acupuncture therapy; NAT: nonacupuncture therapy; CPM : Chinese patent medicine; NSAIDs: nonsteroidal anti-inflammatory drugs; MT: medication therapy.
Figure 2Summary of the AMSTAR-2 assessments.
Figure 3Graphical representation of the AMSTAR-2 assessments.
Quality of evidence included systematic reviews with GRADE.
| Author; year | Outcomes | Studies (participants) | Limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Quality |
|---|---|---|---|---|---|---|---|---|
| Deng et al. [ | Response | |||||||
| AT versus SAT | 12 (933) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| VAS | ||||||||
| AT versus MT | 3(162) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| AT versus CPM | 2 (145) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| AT + herbal versus MT | 2 (166) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
|
| ||||||||
| Zhang et al. [ | Response | |||||||
| AT versus SAT | 4 (694) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| AT versus NSAIDs | 3 (168) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| VAS | ||||||||
| AT versus SAT | 4 (693) | 0 | −1② | 0 | 0 | −1⑤ | Low | |
| AT versus NSAIDs | 2 (102) | −1① | −1② | 0 | 0 | −1⑤ | Very low | |
| Headache days | ||||||||
| AT versus SAT | 3 (754) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| Headache index | ||||||||
| AT versus NSAIDs | 3 (168) | −1① | −1② | 0 | −1④ | −1⑤ | Very low | |
|
| ||||||||
| Lin and Xiao [ | Response | |||||||
| AT versus MT | 9 (598) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| VAS | ||||||||
| AT versus MT | 4 (236) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
|
| ||||||||
| Li and Luo [ | Response | |||||||
| AT versus SAT (after treatment) | 2 (48) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| VAS | ||||||||
| AT versus SAT (after treatment) | 3 (154) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| AT versus SAT (within 2 months) | 3 (152) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
| AT versus SAT (more than 2 months) | 2 (103) | −1① | 0 | 0 | −1④ | −1⑤ | Very low | |
|
| ||||||||
| Linde et al. [ | Response | |||||||
| AT versus SAT (within 2 months) | 4 (1093) | 0 | 0 | 0 | 0 | 0 | High | |
| AT versus SAT (3-4 months) | 4 (703) | 0 | 0 | 0 | 0 | 0 | High | |
| AT versus SAT (5-6 months) | 4 (723) | 0 | 0 | 0 | 0 | 0 | High | |
| AT versus SAT (more than 6 months) | 1 (30) | 0 | 0 | 0 | −1④ | 0 | Moderate | |
| Headache days | ||||||||
| AT versus SAT (within 2 months) | 4 (682) | 0 | 0 | 0 | 0 | 0 | High | |
| AT versus SAT (3-4 months) | 4 (653) | 0 | 0 | 0 | 0 | 0 | High | |
| AT versus SAT (5-6 months) | 4 (670) | 0 | 0 | 0 | 0 | 0 | High | |
| Headache intensity | ||||||||
| AT versus SAT (3-4 months) | 4 (655) | 0 | 0 | 0 | −1④ | 0 | Moderate | |
| AT versus SAT (5-6 months) | 4 (670) | 0 | 0 | 0 | 0 | 0 | High | |
| Safety | ||||||||
| AT versus SAT | 3 (277) | 0 | −1② | 0 | −1④ | 0 | Low | |
| AT versus NAT | 1 (207) | 0 | −1② | 0 | −1④ | 0 | Low | |
|
| ||||||||
| Hao et al. [ | Headache days | |||||||
| AT versus SAT (after treatment) | 5 (729) | −① | −1② | 0 | 0 | 0 | Low | |
| AT versus SAT (within 3 months) | 3 (510) | −① | 0 | 0 | −1④ | 0 | Low | |
| AT versus SAT (more than 3 months) | 4 (684) | −① | 0 | 0 | −1④ | 0 | Low | |
|
| ||||||||
| Davis et al. [ | Headache days | |||||||
| AT versus SAT (during treatment) | 5 (729) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| AT versus SAT (20–25 weeks) | 4 (723) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| Headache intensity | ||||||||
| AT versus SAT (during treatment) | 3 (199) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
| AT versus SAT (20–25 weeks) | 4 (713) | −1① | 0 | 0 | 0 | −1⑤ | Low | |
|
| ||||||||
| Sun and Gan [ | Headache intensity | |||||||
| AT versus SAT (1 month later) | 6 (762) | −1① | 0 | 0 | 0 | 0 | Moderate | |
| AT versus SAT (2 months later) | 4 (681) | −1① | 0 | 0 | 0 | 0 | Moderate | |
AT: acupuncture therapy; SAT: sham acupuncture therapy; NAT: nonacupuncture therapy; CPM : Chinese patent medicine; NSAIDs: nonsteroidal anti-inflammatory drugs; MT: medication therapy; VAS: visual analog scale; ①: the design of the experiment with a large bias in random, distributive hiding or blind; ②: the confidence interval overlaps less, the heterogeneity test P is very small, and the I2 is larger; ③: confidence interval is not narrow enough; ④: funnel graph asymmetry; ⑤: fewer studies are included and there may be greater publication bias.